Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140031/S202

Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve

Edwards Lifesciences, LLC · Decision date Oct 22, 2026

MEDTECHLEDGER EXPLANATIONP140031/S202

What did the FDA approve?

On 2026-10-22, FDA recorded an approval decision (APPR) for PMA supplement P140031/S202, submitted by Edwards Lifesciences, LLC under the Normal 180 Day Track No User Fee supplement type. The supplement reason is a location change covering manufacturer, sterilizer, packager or supplier. The device category is a percutaneously delivered aortic valve prosthesis, product code NPT, in the Cardiovascular specialty.

The recorded scope is narrow: approval of a manufacturing site at CENTERPIECE, Bulevar La Encantada Industrial, Parque Industrial El Floride, Seccion La Encantada # 11530, Tijuana, Baja California, Mexico 22250, for terminal ethylene oxide sterilization. This supplement does not represent a new approval of the Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve system as a whole. The source record includes no documents, so the underlying review memorandum and any site-specific conditions are not available here.

FDA approval order statement

approval for a manufacturing site located at CENTERPIECE (Bulevar La Encantada Industrial, Parque Industrial El Floride, Seccion La Encantada # 11530, Tijuana Baja California, Mexico 22250) for terminal ethylene oxide sterilization.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Oct 22, 2026
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P140031/S202
Regulatory pathway
PMA supplement
Product code
NPT
Decision code
APPR
Decision date
Oct 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Aortic valve, prosthesis, percutaneously delivered.

Product code
NPT
FDA device class
3

For the original device and its historical approval scope, see PMA P140031. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P140031 · Original PMA

    SAPIEN 3 TRANSCATHETER HEART VALVE AND ACCESSORIES

  2. P140031/S202 received

    Application receipt date recorded by FDA.

  3. P140031/S209 · Related supplement

    Edwards Crimper (9600LDS23, 9600LDS26, 9600LDS29, 9750CM20, 9750CM23, 9750CM26, 9750CM29)

  4. P140031/S202 · FDA decision

    Normal 180 Day Track No User Fee

  5. P140031/S210 · Related supplement

    Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX), Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (9750TFX)

Timeline entries are records held by MedtechLedger for P140031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140031

Explore the linked device profile

Other records with product code NPT

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records